|
1
|
Kavanagh BD, Pan CC, Dawson LA, Das SK, Li
XA, Ten Haken RK and Miften M: Radiation dose-volume effects in the
stomach and small bowel. Int J Radiat Oncol Biol Phys. 76:(3
Suppl). S101–S107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lalla RV, Bowen J, Barasch A, Elting L,
Epstein J, Keefe DM, McGuire DM, Migliorati C, Nicolatou-Galitis O,
Peterson DE, et al: MASCC/ISOO clinical practice guidelines for the
management of mucositis secondary to cancer therapy. Cancer.
120:1453–1461. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brizel DM, Wasserman TH, Henke M, Strnad
V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W and
Sauer R: Phase III randomized trial of amifostine as a
radioprotector in head and neck cancer. J Clin Oncol. 18:3339–3345.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jellema AP, Slotman BJ, Muller MJ, Leemans
CR, Smeele LE, Hoekman K, Aaronson NK and Langendijk JA:
Radiotherapy alone, versus radiotherapy with amifostine 3 times
weekly, versus radiotherapy with amifostine 5 times weekly: A
prospective randomized study in squamous cell head and neck cancer.
Cancer. 107:544–553. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakamura H, Arakawa K, Itakura H,
Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M,
Yamamoto A, et al: Primary prevention of cardiovascular disease
with pravastatin in Japan (MEGA Study): A prospective andomized
controlled trial. Lancet. 368:1155–1163. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenson RS, Tangney CC and Casey LC:
Inhibition of proinflammatory cytokine production by pravastatin.
Lancet. 353:983–984. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holler V, Buard V, Gaugler MH, Guipaud O,
Baudelin C, Sache A, Mdel Perez R, Squiban C, Tamarat R, Milliat F
and Benderitter M: Pravastatin limits radiation-induced vascular
dysfunction in the skin. J Invest Dermatol. 129:1280–1291. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Haydont V, Bourgier C, Pocard M, Lusinchi
A, Aigueperse J, Mathé D, Bourhis J and Vozenin-Brotons MC:
Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in
human fibrosis explants and improves radiation-induced intestinal
fibrosis in rats. Clin Cancer Res. 13:5331–5340. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haydont V, Gilliot O, Rivera S, Bourgier
C, François A, Aigueperse J, Bourhis J and Vozenin-Brotons MC:
Successful mitigation of delayed intestinal radiation injury using
pravastatin is not associated with acute injury improvement or
tumor protection. Int J Radiat Oncol Biol Phys. 68:1471–1482. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gaugler MH, Vereycken-Holler V, Squiban C,
Vandamme M, Vozenin-Brotons MC and Benderitter M: Pravastatin
limits endothelial activation after irradiation and decreases the
resulting inflammatory and thrombotic responses. Radiat Res.
163:479–487. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mahmoudi M, Gorenne I, Mercer J, Figg N,
Littlewood T and Bennett M: Statins use a novel Nijmegen breakage
syndrome-1-dependent pathway to accelerate DNA repair in vascular
smooth muscle cells. Circ Res. 103:717–725. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nübel T, Damrot J, Roos WP, Kaina B and
Fritz G: Lovastatin protects human endothelial cells from killing
by ionizing radiation without impairing induction and repair of DNA
double-strand breaks. Clin Cancer Res. 12:933–939. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ostrau C, Hülsenbeck J, Herzog M, Schad A,
Torzewski M, Lackner KJ and Fritz G: Lovastatin attenuates ionizing
radiation-induced normal tissue damage in vivo. Radiother Oncol.
92:492–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jenrow KA, Liu J, Brown SL, Kolozsvary A,
Lapanowski K and Kim JH: Combined atorvastatin and ramipril
mitigate radiation-induced impairment of dentate gyrus
neurogenesis. J Neurooncol. 101:449–456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wedlake LJ, Silia F, Benton B, Lalji A,
Thomas K, Dearnaley DP, Blake P, Tait D, Khoo VS and Andreyev HJ:
Evaluating the efficacy of statins and ACE-inhibitors in reducing
gastrointestinal toxicity in patients receiving radiotherapy for
pelvic malignancies. Eur J Cancer. 48:2117–2124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Withers HR and Elkind MM: Radiosensitivity
and fractionation response of crypt cells of mouse jejunum. Radiat
Res. 38:598–613. 1969. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tian J, Doi H, Saar M, Santos J, Li X,
Peehl DM and Knox SJ: Radioprotection and cell cycle arrest of
intestinal epithelial cells by darinaparsin, a tumor
radiosensitizer. Int J Radiat Oncol Biol Phys. 87:1179–1185. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Potten CS and Grant HK: The relationship
between ionizing radiation-induced apoptosis and stem cells in the
small and large intestine. Br J Cancer. 78:993–1003. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnston CJ, Hernady E, Reed C, Thurston
SW, Finkelstein JN and Williams JP: Early alterations in cytokine
expression in adult compared to developing lung in mice after
radiation exposure. Radiat Res. 173:522–535. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cho H, Matsumoto S, Fujita Y, Kuroda A,
Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara PN, et al:
Trametinib plus 4-methylumbelliferone exhibits antitumor effects by
ERK blockade and CD44 downregulation and affects PD1 and PD-L1 in
malignant pleural mesothelioma. J Thorac Oncol. Nov 17–2016.(Epub
ahead of print).
|
|
21
|
Rotolo JA, Kolesnick R and Fuks Z: Timing
of lethality from gastrointestinal syndrome in mice revisited. Int
J Radiat Oncol Biol Phys. 73:6–8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hauer-Jensen M, Denham JW and Andreyev HJ:
Radiation enteropathy-pathogenesis, treatment and prevention. Nat
Rev Gastroenterol Hepatol. 11:470–479. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Doi H, Kamikonya N, Takada Y, Fujiwara M,
Tsuboi K, Miura H, Inoue H, Tanooka M, Nakamura T, Shikata T, et
al: Long-term sequential changes of radiation proctitis and
angiopathy in rats. J Radiat Res. 53:217–224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Potten CS: Radiation, the ideal cytotoxic
agent for studying the cell biology of tissues such as the small
intestine. Radiat Res. 161:123–136. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gomez DR, Hong DS, Allen PK, Welsh JS,
Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R and Rice DC:
Patterns of failure, toxicity, and survival after extrapleural
pneumonectomy and hemithoracic intensity-modulated radiation
therapy for malignant pleural mesothelioma. J Thorac Oncol.
8:238–245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soto DE, Daignault S, Sandler HM and Ray
ME: No effect of statins on biochemical outcomes after radiotherapy
for localized prostate cancer. Urology. 73:158–162. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gauthaman K, Manasi N and Bongso A:
Statins inhibit the growth of variant human embryonic stem cells
and cancer cells in vitro but not normal human embryonic stem
cells. Br J Pharmacol. 157:962–973. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gabryś D, Dörfler A, Yaromina A, Hessel F,
Krause M, Oertel R and Baumann M: Effects of lovastatin alone or
combined with irradiation on tumor cells in vitro and in vivo.
Strahlenther Onkol. 184:48–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fritz G, Brachetti C and Kaina B:
Lovastatin causes sensitization of HeLa cells to ionizing
radiation-induced apoptosis by the abrogation of G2 blockage. Int J
Radiat Biol. 79:601–610. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zaorsky NG, Buyyounouski MK, Li T and
Horwitz EM: Aspirin and statin nonuse associated with early
biochemical failure after prostate radiation therapy. Int J Radiat
Oncol Biol Phys. 84:e13–e17. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Larner J, Jane J, Laws E, Packer R, Myers
C and Shaffrey M: A phase I–II trial of lovastatin for anaplastic
astrocytoma and glioblastoma multiforme. Am J Clin Oncol.
21:579–583. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Konings IR, van der Gaast A, van der Wijk
LJ, de Jongh FE, Eskens FA and Sleijfer S: The addition of
pravastatin to chemotherapy in advanced gastric carcinoma: A
andomized phase II trial. Eur J Cancer. 46:3200–3204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kastan MB and Bartek J: Cell-cycle
checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koga T, Shimada Y, Kuroda M, Tsujita Y,
Hasegawa K and Yamazaki M: Tissue-selective inhibition of
cholesterol synthesis in vivo by pravastatin sodium, a
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim
Biophys Acta. 1045:115–120. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alberton M, Wu P, Druyts E, Briel M and
Mills EJ: Adverse events associated with individual statin
treatments for cardiovascular disease: An indirect comparison
meta-analysis. QJM. 105:145–157. 2012. View Article : Google Scholar : PubMed/NCBI
|
